Update on ICOS: A Possible Target for Turning-Off Autoimmunity

Title: Update on ICOS: A Possible Target for Turning-Off Autoimmunity

Volume: 3 Issue: 3

Author(s): Priya Sakthivel

Affiliation:

Keywords: ICOS, ICOSL (B7RP-1), co-stimulatory molecules, autoimmune disease

Abstract: Inducible Co-stimulator (ICOS) is one of the co-stimulatory molecules that are unregulated within hours after TCR engagement. The interaction between ICOS and its ligand ICOSL positively co-stimulates T cell activation and proliferation. Thus, ICOS/ICOSL pathway contributes to one of the predisposing factors for autoimmune condition. Therefore, the positive co-stimulatory properties of ICOS are now being regarded as a possible and potential target for treating autoimmune disorders. Several in vivo studies have confirmed the amelioration of autoimmune disease by targeting ICOS pathway. This mini-review comprehensively describes the updated issues regarding ICOS from their discovery and functional consequences (at both genetic and protein aspects) to the recent patents in targeting ICOS pathway for turning-off immune responses in autoimmunity.

Cite this article as:

Sakthivel Priya, Update on ICOS: A Possible Target for Turning-Off Autoimmunity, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2009; 3 (3) . https://dx.doi.org/10.2174/187221409789104755